SCHEDULE: Invus Group Discloses Stake in Silence Therapeutics

A filing reveals that Invus Public Equities, L.P. and affiliated entities now collectively beneficially own 7.0% of Silence Therapeutics plc's ordinary shares.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership of Silence Therapeutics plc.
• As of June 30, 2026, Invus Public Equities, L.P. beneficially owns 8,707,287 ordinary shares, represented by 2,902,429 American Depositary Shares (ADSs).
• Avicenna Life Sci Master Fund LP beneficially owns 1,227,027 ordinary shares, represented by 409,009 ADSs.
• Each ADS represents three ordinary shares.
• Collectively, the Reporting Persons (including affiliated entities like Invus PE Advisors, Global Management, Siren, Avicenna GP, Ulys, and Raymond Debbane) may be deemed beneficial owners of a total of 9,934,314 shares.
• This collective ownership represents 7.0% of the Issuer's outstanding ordinary shares.
• The filing states that these securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine Schedule 13G filing disclosing beneficial ownership changes rather than announcing new strategic or financial developments.

Positives

• Increased institutional interest indicated by the reporting persons' stake.
• Clear disclosure of beneficial ownership, promoting transparency.

Negatives

• No new financial or strategic information is provided, only ownership details.

Risks

• Potential for future changes in beneficial ownership could impact share price volatility.
• The concentration of ownership by a single group could influence corporate actions.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common in the biotechnology and pharmaceutical sectors as investment funds often take significant stakes. This filing indicates a notable investment by the Invus Group in Silence Therapeutics, a company focused on RNAi therapeutics.

Stakeholder Impact

• Shareholders: May view increased institutional ownership positively, but the lack of new strategic information limits immediate impact.
• Management: Will be aware of the significant stake held by Invus Group, potentially influencing future board discussions or strategic decisions.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Monitoring future filings from Invus Group and its affiliates for any further changes in beneficial ownership.
• Observing Silence Therapeutics plc's strategic developments and financial performance.

Key Dates

Keywords

Silence Therapeutics, Schedule 13G, Beneficial Ownership, Invus Group, ADS, Investment Fund, Shareholder